General Objectives
The National Haemoglobinopathy Panel (NHP) Cellular Therapy Operational Group (CTG) is a subgroup of the NHP. The CTG provides a national forum for discussion of cellular therapy (CT) matters impacting adult and paediatric haemoglobinopathy patients proceeding to hematopoietic stem cell transplantation (HSCT) and gene therapy (GT), either following approval by the NHP, or via other commissioning eligibility. This operational group aims to create harmonisation of practices and protocols for services, create a forum for data collection, case/outcome reviews and responses, and drive research relating to cellular therapies.
Meetings
The CTG group meets once every month for their stand-alone meeting, where operational matters such as protocols/SOPs, emerging issues, problem-solving and research are discussed. The CTG also carry out in-depth cellular therapy-focussed discussions relating to specific patients who are either referred from the main NHP MDT in need of more CT-based review, or patients currently undergoing CT who need input from specialist haemoglobinopathy transplant/CT experts. The latter referrals are usually referred by the responsible transplant teams.
Key CTG members also attend the monthly NHP MDT meetings, providing vital input for cellular therapy approvals for patients discussed.
Attendees
Attendees for the CTG meetings include transplant/cellular therapy physicians, red cell clinicians, HCC clinical representatives and CNS representatives, pharmacists, researchers from all regions. All of whom are vital contributors to the workings of the CTG.
Structure
The CTG leadership is formed of NHP Chair (Dr Kate Gardner) and a CRG lead/representative (Dr Subarna Chakravorty) as executive Co-Chairs, as well as three clinical cohort leads covering adult sickle cell disorder (Dr Victoria Potter), adult thalassaemia (Dr Ben Carpenter), and paediatrics (Professor Josu de la Fuente).